[go: up one dir, main page]

WO1999030718A3 - PROSTAGLANDIN E2/F2α COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL - Google Patents

PROSTAGLANDIN E2/F2α COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL Download PDF

Info

Publication number
WO1999030718A3
WO1999030718A3 PCT/US1998/026609 US9826609W WO9930718A3 WO 1999030718 A3 WO1999030718 A3 WO 1999030718A3 US 9826609 W US9826609 W US 9826609W WO 9930718 A3 WO9930718 A3 WO 9930718A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostaglandin
sexual arousal
combination
treating
treating impotence
Prior art date
Application number
PCT/US1998/026609
Other languages
French (fr)
Other versions
WO1999030718A2 (en
Inventor
Nathan Earl Scott
Original Assignee
Nathan Earl Scott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/992,946 external-priority patent/US5981593A/en
Priority claimed from US09/038,378 external-priority patent/US5962528A/en
Application filed by Nathan Earl Scott filed Critical Nathan Earl Scott
Priority to CA002314369A priority Critical patent/CA2314369A1/en
Priority to EP98963194A priority patent/EP1059926A2/en
Priority to AU18272/99A priority patent/AU1827299A/en
Publication of WO1999030718A2 publication Critical patent/WO1999030718A2/en
Publication of WO1999030718A3 publication Critical patent/WO1999030718A3/en
Priority to US09/422,031 priority patent/US6291528B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method of treating and a composition for treating erectile dysfunction in a male patient or female sexual arousal dysfunction, comprising the step of administering to the patient a unit dose of a formulation comprising an effective amount of a prostaglandin, namely prostaglandin E1, prostaglandin E2, or pharmaceutically acceptable salts or derivatives thereof, wherein the prostaglandin is formulated with a small amount of prostaglandin Fα2 together with a pharmaceutically acceptable delivery medium and/or a lubricant. The method also contemplates PGE2 with phentolamine mesylate, with or without PGF2α.
PCT/US1998/026609 1991-07-03 1998-12-15 PROSTAGLANDIN E2/F2α COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL WO1999030718A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002314369A CA2314369A1 (en) 1997-12-18 1998-12-15 Prostaglandin e2/f2.alpha. combination for treating impotence and enhancing sexual arousal
EP98963194A EP1059926A2 (en) 1997-12-18 1998-12-15 PROSTAGLANDIN E 2?/F 2$g(a)? COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL
AU18272/99A AU1827299A (en) 1997-12-18 1998-12-15 Prostaglandin e2/f2alpha combination for treating impotence and enhancing sexual arousal
US09/422,031 US6291528B1 (en) 1991-07-03 1999-10-20 Prostaglandin E1/F2 in combination with prostaglandin F2α for enhancing female sexual arousal

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/992,946 US5981593A (en) 1991-07-03 1997-12-18 Prostaglandin E2 treatment of impotence
US08/992,946 1997-12-18
US508798A 1998-01-09 1998-01-09
US09/005,087 1998-01-09
US09/038,378 1998-03-11
US09/038,378 US5962528A (en) 1991-07-03 1998-03-11 Prostaglandin E2 /F2α combination for treating impotence

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/038,378 Continuation-In-Part US5962528A (en) 1991-07-03 1998-03-11 Prostaglandin E2 /F2α combination for treating impotence

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/422,031 Continuation-In-Part US6291528B1 (en) 1991-07-03 1999-10-20 Prostaglandin E1/F2 in combination with prostaglandin F2α for enhancing female sexual arousal

Publications (2)

Publication Number Publication Date
WO1999030718A2 WO1999030718A2 (en) 1999-06-24
WO1999030718A3 true WO1999030718A3 (en) 1999-09-10

Family

ID=27357802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/026609 WO1999030718A2 (en) 1991-07-03 1998-12-15 PROSTAGLANDIN E2/F2α COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL

Country Status (5)

Country Link
EP (1) EP1059926A2 (en)
CN (1) CN1282249A (en)
AU (1) AU1827299A (en)
CA (1) CA2314369A1 (en)
WO (1) WO1999030718A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US7388029B2 (en) 2000-03-31 2008-06-17 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US7407987B2 (en) 2000-03-31 2008-08-05 Duke University Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
USRE43372E1 (en) 1999-03-05 2012-05-08 Duke University C16 unsaturated FP-selective prostaglandins analogs
US9346837B2 (en) 2000-03-31 2016-05-24 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
AU3713600A (en) 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
CA2362918A1 (en) * 1999-03-08 2000-09-14 Elizabeth Stoner Methods and compositions for treating erectile dysfunction
IL139454A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
ATE352300T1 (en) * 2000-05-12 2007-02-15 Novalar Pharmaceuticals Inc COMPOSITION CONSISTING OF PHENTOLAMINE MESYLATE AND USE THEREOF
SE0100158D0 (en) * 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere's disease and tinnitus
WO2010040556A2 (en) * 2008-10-10 2010-04-15 Milux Holding Sa Stimulation of sexually responsive tissue of the vulva
US9757330B2 (en) 2013-10-18 2017-09-12 Industrial Technology Research Institute Recipe for in-situ gel, and implant, drug delivery system formed thereby

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917864A (en) * 1973-02-12 1975-11-04 Sultanali M M Karim Use of prostaglandins E and F for induction of labor
US4005221A (en) * 1974-04-01 1977-01-25 Karim Sultanali M M Use of prostaglandins to induce menstruation
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
EP0357581A1 (en) * 1988-09-02 1990-03-07 AMSU, Ltd. Composition for the treatment of erectile dysfunction
WO1991016021A1 (en) * 1990-04-25 1991-10-31 Alza Corporation Treatment of erectile dysfunction
WO1993000894A1 (en) * 1991-07-03 1993-01-21 Scott Nathan E Prostaglandin e2 treatment of impotence
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917864A (en) * 1973-02-12 1975-11-04 Sultanali M M Karim Use of prostaglandins E and F for induction of labor
US4005221A (en) * 1974-04-01 1977-01-25 Karim Sultanali M M Use of prostaglandins to induce menstruation
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
EP0357581A1 (en) * 1988-09-02 1990-03-07 AMSU, Ltd. Composition for the treatment of erectile dysfunction
WO1991016021A1 (en) * 1990-04-25 1991-10-31 Alza Corporation Treatment of erectile dysfunction
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
WO1993000894A1 (en) * 1991-07-03 1993-01-21 Scott Nathan E Prostaglandin e2 treatment of impotence
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE43372E1 (en) 1999-03-05 2012-05-08 Duke University C16 unsaturated FP-selective prostaglandins analogs
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
US7388029B2 (en) 2000-03-31 2008-06-17 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US7407987B2 (en) 2000-03-31 2008-08-05 Duke University Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US8906962B2 (en) 2000-03-31 2014-12-09 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US9346837B2 (en) 2000-03-31 2016-05-24 Duke University Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US9579270B2 (en) 2000-03-31 2017-02-28 Duke University Compositions and methods for treating hair loss using non-naturally occurring prostaglandins

Also Published As

Publication number Publication date
CN1282249A (en) 2001-01-31
CA2314369A1 (en) 1999-06-24
AU1827299A (en) 1999-07-05
EP1059926A2 (en) 2000-12-20
WO1999030718A2 (en) 1999-06-24

Similar Documents

Publication Publication Date Title
WO1999030718A3 (en) PROSTAGLANDIN E2/F2α COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL
Waldhauser et al. Efficiency and side effects of prostaglandin El in the treatment of erectile dysfunction
EP0962225A3 (en) Use of phentolamine for the manufacture of a medicament for the treatment of erectile dysfunction
CA2296373C (en) Composition and method for treating penile erectile dysfunction
NO924032D0 (en) TREATMENT OF ERECTIVE FAILURE
ES2152412T3 (en) PHARMACEUTICALLY STABLE PREPARATION OF OXALIPLATINO.
GR3032251T3 (en) Compositions containing prostaglandin e1 and/or troxerutine complexed with phosphatidylcholine for topical treatment of erectile impotence
DE69933128D1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EFFECTIVE DYSFUNCTION
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
NZ503890A (en) Oral contraceptives comprising non-uterotrophic anti-estrogens and progestin
BR0308137A (en) Constant Release Drug Formulations Containing a Vehicle Peptide
EA200400007A1 (en) PHARMACEUTICAL COMPOSITION FOR THE EFFICIENT INTRODUCTION OF APOMORPHIN, 6aR - (-) - N-PROPYL-NORAPOMORPHIN, THEIR DERIVATIVES AND THEIR PROCEDURES
MY106528A (en) Method of treating impotence.
AU6848098A (en) Use of misoprostol or/and misoprostol acid for preparing drug in order to cu re erectile dysfunction
HUP9902094A2 (en) Pge-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction
IL147876A0 (en) Use of agonists of gabab receptors and pharmaceutically acceptable derivatives thereof, in the therapy of maintaining nicotine abstinence-dependent patients
Chew et al. Use of transurethral alprostadil (MUSE)(prostaglandin E1) for glans tumescence in a patient with penile prosthesis
GR3036071T3 (en) Use od moxonidine for the Treatment of neuropathic pain
US20050276865A1 (en) Peroxide compounds for the prevention and treatment of sexual dysfunction in humans
WO2001085188A3 (en) Use of echinacea as a hematinic agent
BR0311423A (en) Pharmaceutical formulation, use of a long-acting progestogen and long-acting androgen dissolved in a pharmaceutically acceptable oily medium, male contraceptive injection kit, and male contraceptive method
IT1247678B (en) METHOD FOR THE TREATMENT OF MALE ERECTIVE IMPOTENCE
AU1564500A (en) Method for obtaining and using a combination of a purine and a nitrogen monoxidedonor for preventing or treating sexual dysfunction
US20040258774A1 (en) Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of a 5-phosphodiaesterase inhibitor for the treatment of female sexual dysfunction
MD1568G2 (en) Method of treatment of the burn disease in the burn shock period

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98812205.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09422031

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/A/2000/005675

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2314369

Country of ref document: CA

Ref document number: 2314369

Country of ref document: CA

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998963194

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998963194

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998963194

Country of ref document: EP